A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM

NCT07142161 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes

Interventions

DRUG: RD13-02 cell infusion

Sponsor

Nanjing Bioheng Biotech Co., Ltd.